Compare Citius Pharmaceuticals Inc (CTXR) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs McDonald's Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while McDonald's Corp trades at $269.26 (market cap $191.08B). The key difference: McDonald's Corp is far larger — about 13051.9× Citius Pharmaceuticals Inc's market cap, and McDonald's Corp pays a 2.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MCD | |
|---|---|---|
Market Cap | $14.64M | $191.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $341.06 |
52-Week Low | $0.53 | $264.54 |
Enterprise Value | $10.86M | $244.79B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
McDonald's (MCD) trades at $268.94, down 2.06% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly EPS results, with a miss in Q3 2025 but beats in Q4 2025 and Q1 2026. Revenue grew to $26.89 billion in 2025, with a net income margin of 31.62%. Recent news highlights the launch of the McDonald's NEXT strategy focusing on automation and better food to win back customers.
The outlook remains supported by strong analyst consensus with a $325.50 price target and 59.68% buy ratings, but risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a dividend yield with a recent $1.86 payout, appealing for income-focused investors amid current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
